The role of CSF markers in the early diagnosis of Alzheimer's disease;De rol van liquormarkers bij de vroege diagnostiek van de ziekte van Alzheimer

Tijdschrift voor Psychiatrie

Volumn 53, Issue 9, 2011, Pages 647-653

  Vos, Stephanie J B ^a   Visser, P J ^b   Verhey, F R J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Early diagnostics

Indexed keywords

ADL DISABILITY; ALZHEIMER DISEASE; AMNESIA; ARTICLE; CEREBROSPINAL FLUID; COGNITION; DISEASE MARKER; EARLY DIAGNOSIS; EUROPE; HUMAN; MILD COGNITIVE IMPAIRMENT; MULTICENTER STUDY; PREVALENCE; PROGNOSIS;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 80052619011     PISSN: 03037339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, e.a. Cerebrospinal fluid tau and A[beta]42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Letters 1999;273:5-8.
2. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-44.
3. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-34. (Pubitemid 43238346)
4. Hulstaert FM, Blennow K, Ivanoiu AM, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, e.a. Improved discrimination of AD patients using [beta]-amyloid(1-42) and tau levels in CSF. Neurology 1999;52:1555-62.
5. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, e.a. CSF Biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385-93.
6. Petersen RC, Smith GE, Wating SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8. (Pubitemid 29120227)
7. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and (beta)-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 2002;59:1729-34. (Pubitemid 35340483)
8. Rossum IA Van, Vos S, Handels R, Visser PJ. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. JAD 2010;20:881-91.
9. Visser PJ, Verhey FRJ, Boada M, Bullock R, De Deyn PP, Frisoni GB, e.a. Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. Neuroepidemiology 2008;30:254-65.
10. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund L-O, Freund-Levi Y, e.a. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009;8:619-27.